Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma
© Akbari et al.; licensee BioMed Central Ltd. 2014
Received: 3 December 2013
Accepted: 4 May 2014
Published: 5 June 2014
Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment.
To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively.
Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls.
Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
KeywordsSD-208 Colorectal cancer SW-48 Immunohistochemistry staining
Colorectal cancer (CRC) is the second leading cause of cancer death among adults, making it as an excellent and desirable area for clinicians and researchers to study[1, 2]. It has been also found that a large proportion of cancers such as CRC display inactivation of the growth factors specially transforming growth factor-β (TGF-β) pathway but they are characterized by increasing the factor production. In man, three isoforms of TGF-β including TGF-β1, TGF-β2 and TGF-β3 have been well characterized[3, 4]. The homology searching has revealed that these proteins share up to 75% amino acid sequences. In spite of the fact that they have demonstrated comparable signaling activities, they are differentially expressed in cell lineages and tissues. It has been also frequently reported that TGF-β is the most effective growth inhibitor for normal epithelial, hematopoietic and immune cells. Studies showed that TGF-β acts as a double-edged sword in the biological processes[3–6]. In addition, it plays important roles in primary tumor progression and in promoting metastasis and has become an attractive target for therapy[5–7]. TGF-β exerts its effects by acting on two types of transmembrane receptors: type I (TGβRI) and type II (TGβRII). These receptors are involved in signal transduction, triggers through interaction of the TGF-β with TGβRII. Once TGF-β binds to TGβRII leads to the recruitment, phosphosphorylation, and activation of TGβRI. Activation of the TGβRI invokes several TGF-β signaling pathway targets and downstream genes[7, 8]. Based on the literature, targeting of TGF-β signaling could be a valuable tool to treatment of human cancers such as CRC, glioblastoma and breast cancer[6–10]. Several studies reported that a series of pyridopyrimidine-based TGβRI kinase inhibitors such as SD-208 could be a powerful approach for the treatment of various cancers. SD-208 is a small-molecule kinase inhibitor that bind to the ATP-binding site of the TGβRI kinase and maintains the enzyme in its inactive configuration[11–13]. Despite advances in our understanding of the molecular and genetic basis of CRC, effective treatment of the disease remains a clinical challenge. As pointed out, TGF-β promotes cell proliferation, development, invasion and metastasis in several types of tumors. It is thought that TGβRI inhibitor may have a therapeutic benefit in CRC; therefore, pharmacological blockade of the TGF-β signaling pathway has been proposed as a benefit strategy for CRC therapy. In the current study, SW-48, colon adenocarcinoma cell line was treated with different doses of SD-208, an anti-cancer agent. We evaluated the effects of SD-208 on cell proliferation and differentiation in vitro and in vivo.
Human colorectal adenocarcinoma cell line with pathologic differentiation grade of the original tumors IV, SW-48, was obtained from National Cell Bank of Iran (NCBI) affiliated to Pasteur Institute (Tehran, Iran). The cell line was grown in RPMI-1640 medium (Gibco; Germany) containing 25 mM D-glucose, 4 mM L-glutamine and 1 mM sodium pyruvate and supplemented with 5% (v/v) heat inactivated fetal bovine serum (FBS) (Gibco; Germany), 2 mM glutamax (Gibco; Germany), 100 units/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml amphoterycin (Gibco; Germany) in culture flask 25 cm2 (SPL Life Sciences; South Korea). The cells were kept at 37°C in a humidified 95% atmosphere, 5% CO2 atmosphere incubator designated as culture at a steady-state condition. Cell viability was assessed using trypan blue exclusion test and routinely found to all flasks contain more than 95% viable cells.
Chemical description and biological activity TGβRI kinase inhibitor, SD-208
SD-208 (Sigma Aldrich; Belgium) is a selective and orally active pyridopyrimidine type TGβRI kinase inhibitor with an IC50 of approximately 35 nmol/L against TβRI kinase activity in vitro. The drug was dissolved in 100% dimethylsulfoxide (DMSO; Sigma Aldrich; Belgium) and prepared as stock solutions of 5 mM in DMSO and kept at −20°C until use.
Animal model implanted with adenocarcinoma cell line (SW-48) and treatment protocol
6–week–old female athymic C56BL/6 nude mice (n = 8 per group) were obtained from Omid Institute for Advanced Biomodels (Tehran, Iran). Animals were kept under optimized hygienic conditions in an individually ventilated cage system. The mice were fed with autoclaved commercial diet and water ad libitum. All animal experiments were carried out according to the Tehran University of Medical Sciences, Ethical Committee Acts and were approved by the TUMS Ethical Committee. In order to establish the xenograft model of SW-48 cell line, the cells were cultured in RPMI 1640 containing 10 percent FBS in 75 cm2 cell culture flasks. The cells were trypsinized and harvested. After washing, totally 5 × 106 cells were resuspended and inoculated subcutaneously at a 200 μl volume of serum–free medium into the flank of the animals. Tumor growth was measured twice a week. The volume of tumors was calculated by standard formula (Length × width2 × 0.52) and growth curve was drawn (Tomayko, 1989). Xenograft tumors were allowed to reach a size of 100 mm3. Then, the animals were randomly divided into two groups of 8 to receive either SD-208 (50 mg/kg/d) or vehicle orally for three weeks. Control animals were received daily drug-free and DMSO-containing deionized water (vehicle). At the end of the treatment period, mice were killed by CO2 inhalation and obtained tumors after isolating from animal were fixed in 10% buffered formalin and were subjected to histopathological staining.
Histopathological diagnosis and immunohistochemistry
Hematoxylin and eosin (H&E) staining for SW-48 tumor confirmation and immunohistochemistry (IHC) staining for Ki-67 and CD34 markers were done. Then, five sections at routine thickness (5 μm) were prepared from the formalin-fixed paraffin-embedded tissue blocks and floated onto charged glass slides (Super-Frost Plus, Fisher Scientific). The slides then were dried overnight at 60°C. For the revision of the histopathological diagnosis and confirmation of developed the SW-48 cell-derived tumors, two hemotoxylin and eosin stained sections were obtained from tissue blocks. Immunohistochemistry carried out for the evaluation of SD-208 effects on proliferation and angiogenesis (Ki-67 and CD34 marker, respectively) in the tumor xenografts. For this, three sections were deparaffinized and hydrated using graded concentrations of ethanol to deionized water from each block. These sections were stained immunohistochemically using three steps-indirect streptavidin method for Monoclonal Mouse Anti-Human Ki-67 Antigen (MIB-1), clone M 7240 (Dako; Denmark) and Monoclonal Mouse Anti-Human CD34, clone QBEnd-10 (Dako; Denmark). Negative controls were obtained by omitting the primary antibody for aforementioned markers under identical test condition. Sections from a lymph node with follicular lymphoid hyperplasia known to be immunoreactive for Ki-67 and CD34 were used as a positive control (as recommended by the manufacturer).
Statistical analysis was performed, and statistical significance of differences between data was evaluated by independent sample Student’s t-test for tumor markers (Ki-67 and CD34) and one-way analysis of variance (ANOVA) followed by Tukey’s post tests for multiple comparisons of differences between treatment groups. Data were expressed as mean ± SEM (the standard error of the mean). P values less than 0.05 were considered to indicate statistically significant differences between data sets.
In vitro effects of SD-208 on SW-48 cell line
Effects of SD-208 on growth of SW-48 cell line
Inhibition rate (IR)%
OD value (mean ± SEM)
Concentration of SD-208 (μM)
2.06 ± 0.085
1.64 ± 0.098
1.61 ± 0.093
1.54 ± 0.099
1.51 ± 0.098
2.14 ± 0.079
1.73 ± 0.081
1.71 ± 0.087
1.69 ± 0.097
1.62 ± 0.098
Colon adenocarcinoma model
Ki-67 and CD34 expressions in the tumor xenografts
The results from the immunochemical assay indicated that Ki-67 was predominantly expressed in the nucleus. As already pointed out, the immunohistochemically stained tumors with anti-Ki-67 showed positively brown nuclear in the studied tissues (Figure 5). The Ki-67 expression levels between the test and control groups did not show significant changes (P > 0.05). Immunohistochemical staining using anti-CD34 antibody on tumor tissues from either treated or untreated nude mice with SD-208 showed cytoplasmic membrane of endothelial cells in brown color and marked microvessels proliferation (Figure 6).
Despite aggressive surgery, radiotherapy and chemotherapy, treatment of malignant CRC remains formidable. Even though that TGF-β suppresses proliferation of certain carcinoma cells and is well-known to be a tumor suppressor, it promotes tumor development, progression and metastasis in human cancers including CRC, glioma, osteosarcoma, breast, lung and pancreatic cancers[14–16]. The insights into the role of the TGF-β signaling in carcinogenesis importantly have come due to experimental study on animal models. Understanding the mechanisms by which TGF-β signaling regulates tumor development and progression is critical for designing the beneficial therapeutic strategies for the cancers[14, 16–18]. In the last few years, because of availability and easily drug delivery, the targeting of receptor kinases by small-molecule inhibitors has been a profound area of experimental cancer studies[16, 17, 19].
It is thought that pharmacological blockade of the TGF-β signaling pathway by TGβRI inhibitors may be as a potential strategy for cancer therapy[17–19]. For the first time, we evaluated the efficacy of systemic targeting of the TGF-β pathway by a TGβRI kinase inhibitor, SD-208, on a high-grade colon adenocarcinoma cell line, SW-48, in vitro and in developed heterotopic colon tumors in model that shares similarities with human colon cancer. Our findings using MTT and BrdU assays demonstrated that treatment of SW-48 cells with SD-208 using different doses had no significant inhibitory effects on cell growth and proliferation. Our in vitro results were consistent with one study revealing SD-208 can not reduce viability or proliferation of human malignant glioma cells. However, this study showed that SD-208 regulates the growth of glioma in syngeneic mice without changes in proliferation, apoptosis or angiogenesis. Also, other investigators demonstrated that SD-208 failed to inhibit R3T tumor growth or metastasis in athymic nude mice. On the other hand, some studies suggested that the various kinase inhibitors including SD-208, were able to inhibit TGF-β-evoked migration and invasion[20–22]. These results indicated that reduction of tumors was due to regulation of immune surveillance and importantly correlated with tumor-reactive immune regulation and increased immune infiltration[21, 22]. Thereby, it has been commented that SD-208 could be a promising agent for the treatment of human malignancy and other conditions associated with pathological TGF-β activity.
In addition, we revealed that when drinking water contains SD-208 daily, the drug could not inhibit the growth of established heterotopic SW-48 tumors and its progression in nude mice. Further histological analysis indicated that SD-208 had no significant effects on proliferation (Ki-67 positivity) or the number of blood vessels and angiogenesis (CD34 positivity). This is consistent with reports by others showing SD-208 had no effect on the growth of primary and metastatic R3T mammary tumors in athymic nude mice. In the agreement with our results and previous studies, it has been shown that an inhibitor of TGF-β receptor 1 kinase, SM16, lost efficacy against the AB12 mesothelioma model in SCID mice.
Also, we found that SD-208 is not effective in limiting heterotopic tumor growth and not proper to treat established primary tumors settings at least in SW-48 colorectal cancer cells. The failure of SD-208 to inhibit SW-48 tumor growth in nude mice suggests that the suppression of angiogenesis and proliferation could be dependent on cell lineage and cell context. Our results are not the first report suggesting the inability of SD-208 to inhibit angiogenesis and proliferation. Some researchers reported that SD-208 was unable to cause differences in microvessel density in gliomas. Furthermore, a study of two TGF-βR1 inhibitors, SD-093 and SD-208, on two murine mammary carcinoma cell lines (R3T and 4 T1) revealed that SD-208 failed to inhibit R3T tumor growth or metastasis in athymic nude mice. However, SD-208 treatment led to a reduction in microvessel density in mammary tumors.
It is quite understandable that the efficacy of this kinase inhibitor is a controversial issue in cancer treatment. In this regard, several scenarios could be proposed to elucidate the failure of SD-208 as an anti-tumor: (1) genetic alterations such as chromosomal abnormalities and (2) gene mutation in any TGF-β signaling pathway.
We have demonstrated that SD-208, a TGβRI kinase inhibitor, was not able to reduce tumor growth and angiogenesis in a heterotopic human colorectal cancer model. Our results also for the first time indicated that this anti-cancer agent could not potentially have a therapeutic benefit in at least proportion of CRC. To get more insight into the potential biological effects of SD-208 on CRC, different CRC cells with various differentiated status are required to treat with SD-208. Moreover, because of the complexity of TGF-β signaling role and crosstalk with other factors (such as immunochemotactic and angiogenic agents) in the derived tumor microenvironment, designing therapeutic intervention strategies for targeting tumors in this field, should be very carefully.
Transforming growth factor-β
- TGβRI or TβRI:
TGF-β receptor 1, TGβRII or TβRII, TGF-β receptor 2
A colon adenocarcinoma cell line
A TGF-β receptor I kinase inhibitor
Methyl thiazolyl tetrazolium
Hematoxylin and Eosin
This study represents a part of a Ph.D. dissertation by Abolfazl Akbari. We wish to thank the School of Advanced Medical Technologies, the Tehran University of Medical Sciences (TUMS) for financially supporting this study.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.View ArticlePubMedGoogle Scholar
- Kinzler KW, Vogelstein B: The Genetic Basis of Human Cancer. 2002, New York: McGraw-Hill, 583-612. 2Google Scholar
- Luo K, Lodish HF: Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J. 1996, 15: 4485-4496.PubMed CentralPubMedGoogle Scholar
- Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev Cancer. 2003, 3: 807-821. 10.1038/nrc1208.View ArticleGoogle Scholar
- Moustakas A, Heldin CH: Non-Smad TGF-β signals. J Cell Sci. 2005, 118: 3573-3584. 10.1242/jcs.02554.View ArticlePubMedGoogle Scholar
- Miriam Barrios R, Kevin R, Barish O, Rohit B, Zhong L, RS D, Fukiko SH, Yongmei L, Joanna D, Taylor IW, Valbona L, Mark R, Harukazu S, Yoshihide H, Igor J, Jeffrey LW: High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005, 307: 1621-1625. 10.1126/science.1105776.View ArticleGoogle Scholar
- Bierie B, Moses HL: TGF-β and cancer. Cytokine Growth Factor Rev. 2006, 17: 29-40. 10.1016/j.cytogfr.2005.09.006.View ArticlePubMedGoogle Scholar
- Levy L, Hill CS: Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006, 17: 41-58. 10.1016/j.cytogfr.2005.09.009.View ArticlePubMedGoogle Scholar
- Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-β signaling inhibitors for cancer therapy. Nature Rev Drug Discov. 2004, 3: 1011-1022. 10.1038/nrd1580.View ArticleGoogle Scholar
- Jean-Jacques L: The dual role of TGF in human cancer: from tumor suppression to cancer metastasis. ISRN Molecular Biology. 2012, 7: 1-28.Google Scholar
- Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM: Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry. 2005, 44: 2293-2304. 10.1021/bi048851x.View ArticlePubMedGoogle Scholar
- Hill R, Song Y, Cardiff RD, Van Dyke T: Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005, 123: 1001-1011. 10.1016/j.cell.2005.09.030.View ArticlePubMedGoogle Scholar
- Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002, 62: 65-74. 10.1124/mol.62.1.65.View ArticlePubMedGoogle Scholar
- Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Res. 2003, 63: 7791-7798.Google Scholar
- Qipeng F, Miao H, Tao S, Xiaoli Z, Mala S, Bruce L, Xingbo Z, Jing Wu X: Requirement of TGF Signaling for SMO-mediated Carcinogenesis. J Biol Chem. 2010, 47: 36570-36576.Google Scholar
- Bierie B, Harold LM: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006, 6: 506-520. 10.1038/nrc1926.View ArticlePubMedGoogle Scholar
- Uhl M, Steffen A, Jörg W, Markus W, Jing Ying M, Ramona A, Ruban M, Yu-Wang L, Michael P, Ulrich H, Alison M, Darren H, Wolfgang W, Higgins LS, Michael W: SD-208, a novel transforming growth factor-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004, 64: 7954-7961. 10.1158/0008-5472.CAN-04-1013.View ArticlePubMedGoogle Scholar
- Subramanian G, Schwarz RE, Linda H, Glenn M, Sarvajit C, Sundeep D, Michael R: Targeting endogenous transforming growth factor-β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 2004, 64: 5200-5211. 10.1158/0008-5472.CAN-04-0018.View ArticlePubMedGoogle Scholar
- Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, Chung KF: Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther. 2006, 319: 586-594. 10.1124/jpet.106.109314.View ArticlePubMedGoogle Scholar
- Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M: Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006, 12: 4315-4330. 10.1158/1078-0432.CCR-06-0162.View ArticlePubMedGoogle Scholar
- Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007, 67: 2351-2359. 10.1158/0008-5472.CAN-06-2389.View ArticlePubMedGoogle Scholar
- Khalid SM, Delphine J, Pierrick GJ, Maria N, Ryan M, Xiang HP, Duong V, Lauren KD, Alain M, Theresa AG: TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011, 71: 175-184. 10.1158/0008-5472.CAN-10-2651.View ArticleGoogle Scholar
- Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O’Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS: Antitumor activity of TGF-β inhibitor is dependent on the microenvironment. Anticancer Res. 2007, 27: 4149-4158.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.